340B Patient Advisory Committee
Quick links
The 340B Patient Advisory Committee is currently closed. ADAP Advocacy is not recruiting patients and public health stakeholders to serve on this committee.
Committee Members
The committee is open to adding new discussion topics to its meeting agenda. Click here to submit your thoughts to Guy Anthony, chair of the 340B Patient Advisory Committee.
April 29, 2026 - Q2 Meeting
March 19, 2026 - Q1 Meeting
Meeting Presentation - by Dr. Rory Martin, Market Access Technology Solutions, IQVIA
BACK TO TOPCommittee Meetings
AIDS Drug Assistance Programs
Is the 340B Drug Pricing Program the Next ‘Too Big to Fail’? (February 2025)
Resolution Calling for Industry 340B Carveout for State AIDS Drug Assistance Programs (December 2023)
Executive Compensation & Charity Care
Summary: 340B Program Eligibility, Executive Compensation, and Charity Care (October 2023)
Blog: 340B Covered Entities’ Revenue Witnessed Huge Executive Compensation Increases, Alarming Charity Care Decreases (November 2023)
340B Drug Pricing Program: Charity Care Declines & Medical Debt Explodes (November 2024)
340B Drug Pricing Program: Charity Care Declines (November 2024)
340B Drug Pricing Program: Medical Debt Explodes (November 2024)
Patient Medical Debt: Findings from Quantitative Surveying of Patients in the United States (April 2025)
Rebate Model
Safety Net & Charity Care
BACK TO TOPCommittee Policy Assets
ADAP Advocacy
Pioneer Institute for Public Policy Research
Pioneer Institute for Public Policy Research
Urban Institute
BACK TO TOPCommittee Resources
This project is funded by the following corporate entities:
Bristol-Myers Squibb, Genentech, Gilead Sciences, Johnson & Johnson Health Systems, Lilly, Merck, Novartis, Novo Nordisk, Pharmaceutical & Research Manufacturers of America (PhRMA), Pfizer, and ViiV Healthcare.
Transparency statement:
To read our Transparency Statement, click here.
BACK TO TOP